Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

yttrium Y 90 epratuzumab

A radioimmunoconjugate consisting of the anti-CD22 monoclonal antibody epratuzumab chelated to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 epratuzumab binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation. Epratuzumab is a humanized version of the murine monoclonal antibody LL2; CD22 is a B cell-restricted antigen present on the surfaces of mature B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Y 90 Humanized Monoclonal Antibody LL2
Yttrium Y 90 Humanized Monoclonal Antibody LL2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search